Macrosomia Drops With CGM Use

BY SARA FREEMAN
Contributing Writer

ROME — Continuous glucose monitoring during pregnancy was linked to a significant reduction in median birth weight and macrosomia risk in a study of 71 women with type 1 or type 2 diabetes.

The randomized, open study also showed that pregnant women who wore the monitors for 5-7 days, at 4-6 weekly intervals, had better blood glucose control than did women who received standard prenatal care alone.

The study comprised 46 women with type 1 and 25 women with type 2 diabetes. A total of 38 women were randomized to use continuous glucose monitoring (CGM) as an educational tool to inform decision making and future therapeutic changes;

Children in the continuous glucose monitoring group had a 64% lower risk of macrosomia.

DR. MURPHY

the remaining 33 women were randomized to standard care, study investigator Dr. Helen R. Murphy reported Sept. 8 at the annual meeting of the European Association for the Study of Diabetes.

All statistical analyses were performed on an intention-to-treat basis, said Dr. Murphy of Ipswich (England) Hospital.

At weeks 32-36 of gestation, hemoglobin A_{1c} levels were significantly lower in the CGM group than in the standard care group (5.8% vs. 6.4%).

In addition, infants born to women in the CGM group were significantly less likely to have a high birth weight than were those born to women in the standard care group. The mean standard deviation (SD) score for birth weight was 0.9 for infants in the CGM group and 1.6 for those in the standard care group.

"What is even more striking is the complete absence of small-for-gestational age babies in women randomized to standard antenatal care," Dr. Murphy said.

She also noted that there were two infants that had SD scores of above three in the CGM arm, but their mothers had withdrawn from the study before completion.

Compared with children in the standard care arm, the children in the CGM group were at decreased risk (odds ratio 0.36) of macrosomia, defined as a birth weight in the 90th percentile or higher.

CGM was well accepted by the women, according to Dr. Murphy, adding that they wore the monitors on their flank at least once a trimester. The monitors were provided free of charge by Medtronic UK. Ipswich Hospital Diabetes Centre Charity Research Fund and Diabetes UK supported the investigator-led study. ■

Prepregnancy Diabetes Ups Defect Risk

BY HEIDI SPLETE
Senior Writer

Women who are diagnosed with diabetes prior to pregnancy are three to four times more likely to have a child with birth defects, compared with women who don't have diabetes prior to pregnancy, based on results from a study of more than 15,000 live births published online in the American Journal of Obstetrics and Gynecology.

Although previous studies have established pregestational diabetes mellitus (PGDM) as a risk factor for several types of birth defects, the prevalence of maternal diabetes in cases of birth defects has not been well quantified, said Dr. Adolfo Correa, an epidemiologist at the Centers for Disease Control and Prevention.

Dr. Correa and his colleagues reviewed data from 13,030 cases of infants with birth defects and 4,895 control infants. The data came from the National Birth Defects Prevention Study, an ongoing population-based study that includes birth defect surveillance at 10 locations in the United States (Am. J. Obstet. Gynecol. 2008 [doi:10.1016/j.ajog.2008.06.028).

The overall prevalence of PGDM was 2.2% in cases of infants with birth defects (283 cases/13,030 births), compared with 0.5% for the control infants (24 cases/4,895 births). In the birth defects group, 138 mothers had type 1 diabetes and 145 had type 2 diabetes. In the con-